Plasma cell myeloma (PCM) is a devastating disease with a highly heterogeneous outcome, with survival ranging from a few months to longer than 10 years. Treatment of multiple myeloma has changed markedly in the past decade due to the development of new drugs such as bortezomib, lenalidomide and thalidomide, which have greatly improved the outcome of PCM. The clinical and prognostic value of immunophenotyping in PCM remains questionable. The aim of this study was to determine the diagnostic and prognostic significance of CD200 expression in newly diagnosed PCM. We retrospectively reviewed the records of 107 patients newly diagnosed with PCM at Showa University Hospital between January 2004 and September 2013. Expression of CD200 was studied by immunohistochemistry. Clinical and pathological parameters were compared between CD200-positive and CD200-negative cases. CD200-positive PCM cases had lower serum albumin (p = 0.0001) compared to those without CD200 expression. Our results showed no significant difference in median overall survival between patients with CD200-positive and CD200-negative PCM. However, there was a strong correlation between CD200 expression and serum albumin level. In the CD200-negative group, median overall survival was significantly longer in patients who received new drug treatment. These findings suggest that CD200 expression is a useful marker for evaluation of the severity of PCM and that lack of CD200 expression may improve the sensitivity of PCM to therapy with new drugs.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.3960/jslrt.55.121 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Correlation between conventional karyotype, interphase FISH and immunophenotype in risk stratification of newly diagnosed plasma cell myeloma: An observational study.
Med J Armed Forces India
December 2024
Professor (Lab Sciences & Molecular Medicine), Army Hospital (R&R), Delhi Cantt, India.
Background: Plasma cell myeloma (PCM) is a common adult hematological neoplasm of terminally differentiated B-cells resulting in accumulation of monoclonal plasma cells. PCM is heterogeneous disease with survival time varies from months to years, determined by age, stage, cytogenetics abnormalities, and treatment response. There is conflicting evidence in role of immunophenotype as a prognostic indicator.
View Article and Find Full Text PDFGum Arabic Enhances Hair Follicle-Targeting Drug Delivery of Minoxidil Nanocrystal Dispersions.
Biol Pharm Bull
December 2024
Faculty of Pharmacy, Kindai University.
In this study, we attempted to enhance the delivery of minoxidil (MXD) nanocrystals into hair follicles for efficacious hair growth treatment. We applied a bead milling method and designed an MXD nanocrystal dispersion containing methylcellulose (MC) and gum arabic (GA), termed MG-MXD@NP, with a particle size of 110 nm. In vivo studies in C57BL/6 mice showed that MG-MXD@NP improved MXD delivery to the skin tissue, hair bulges, and hair bulbs, resulting in earlier and superior hair growth compared with a commercially available MXD lotion (Riup 5%, CA-MXD).
View Article and Find Full Text PDFCoagulation factor II thrombin receptor as a promising biomarker in breast cancer management.
Open Life Sci
December 2024
Department of General Surgery, The Second Affiliated Hospital of Air Force Medical University, No. 356 of Xinsi Road, Baqiao District, Xi'an, 710038, China.
This study aims to comprehensively investigate the role of coagulation factor II thrombin receptor (F2R) in breast cancer (BC) and to evaluate its potential as a biomarker in this context. Data on female BC were retrieved from the TCGA database. Comparative analyses were performed, including enrichment analysis, tumor immune microenvironment analysis, drug sensitivity testing, molecular docking, and cell-based experiments, to assess the expression and function of F2R in BC.
View Article and Find Full Text PDFFirst-in-human study of 23ME-00610, an antagonistic antibody for genetically validated CD200R1 immune checkpoint, in participants with advanced solid malignancies.
Cancer Res Commun
December 2024
South Texas Accelerated Research Therapeutics, San Antonio, TX, United States.
Purpose: In this Phase 1 portion of a first-in-human Phase 1/2a study (NCT05199272), 23ME-00610 was evaluated in participants with advanced solid malignancies to determine its safety, tolerability, pharmacokinetics, and pharmacodynamics. Exploratory biomarkers were evaluated to examine potential correlates of efficacy and safety.
Patients And Methods: Eligible participants (≥18 years) were administered 23ME-00610 intravenously every 3 weeks using an accelerated titration design followed by a traditional 3+3 design, with an initial dose level of 2 mg.
Sequencing of messenger RNA in the healing process of diabetes foot ulcer.
Front Endocrinol (Lausanne)
December 2024
Department of Vascular Surgery, Affiliated Jinan Central Hospital of Shandong First Medical University, Jinan, China.
Article Synopsis
- Transcriptome analysis of diabetic foot ulcers (DFUs) was conducted using mRNA sequencing to understand the microenvironment changes during wound healing in five patients.
- Wound specimens were collected at initial healing (0%) and after 50% healing, revealing 4,347 differentially expressed genes, predominantly linked to biological processes like cell adhesion and skin barrier formation.
- The study concluded that effective DFU healing is influenced by various factors, particularly inflammation control, angiogenesis, and the proliferation of fibroblasts.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!